Active, not recruitingPhase 3NCT04543617
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
Studying Squamous cell carcinoma of the esophagus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoffmann-La Roche
- Principal Investigator
- Clinical TrialHoffmann-La Roche
- Intervention
- Tiragolumab(drug)
- Enrollment
- 760 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Study locations (30)
- Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, United States
- Cancer Center of Kansas, Wichita, Kansas, United States
- Great Lakes Cancer Center, Williamsville, New York, United States
- Instituto de Investigaciones Metabolicas (Idim), Buenos Aires, Argentina
- Fundacion Favaloro, Buenos Aires, Argentina
- Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina
- Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
- Austin Health, Heidelberg, Victoria, Australia
- St John of God Hospital, Subiaco, Western Australia, Australia
- Tiroler Landeskrankenanstalten Ges.M.B.H., Innsbruck, Austria
- Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria
- Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria
- AKH - Medizinische Universität Wien, Vienna, Austria
- UZ Antwerpen, Edegem, Belgium
- UZ Leuven Gasthuisberg, Leuven, Belgium
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04543617 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the esophagus
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07457528Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCCTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE2NCT07331155A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]Nanjing Leads Biolabs Co.,Ltd
- RECRUITINGPHASE1NCT07503808A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesIDEAYA Biosciences
- RECRUITINGPHASE2NCT07403136Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCCFudan University
- RECRUITINGPHASE1, PHASE2NCT07385001A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCCTang-Du Hospital
- RECRUITINGPHASE2NCT07263919Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)Akeso
- RECRUITINGPHASE2NCT07481058KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal CancerBeijing Konruns Pharmaceutical Co., Ltd.
- RECRUITINGPHASE1NCT07217171A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell CarcinomasEvolveImmune United, Inc
See all trials for Squamous cell carcinoma of the esophagus →